NCT07317115

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

Magnetic Compression Anastomosis in Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes (MAGvMED Study)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: GT Metabolic Solutions, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Compare use of the Magnet System in side-to-side duodeno-ileostomy (Surgery) with semaglutide (Medication).

Detailed description

Compare functional improvement of T2D using the Magnet System in duodeno-ileostomy for intestinal diversion versus semaglutide in eligible participants with obesity (BMI 30 - 40 kg/m2) and T2D (HbA1c ≥ 6.5%).

Conditions

• Obesity (Disorder)
• Obesity & Overweight
• Type 2 Diabetes (T2DM)

Interventions

Type	Name	Description
DEVICE	Magnet System	Magnet System for side-to-side magnetic compression anastomosis in a duodeno-ileostomy bipartition
DRUG	Semaglutide	Semaglutide (up to 2.4mg subcutaneous (SQ) injection weekly or dose tolerated according to side effects); a glucagon-like peptide-1 receptor agonist (GLP-1RA)

Timeline

• Start date: 2026-03-01
• Primary completion: 2027-06-01
• Completion: 2028-06-01
• First posted: 2026-01-05
• Last updated: 2026-02-20

Locations

1 site across 1 country: Canada